Clinical trial
S9912 Combination Chemo in Stage III Ovarian Cancer,
NCT00003896 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00003896 |
|---|---|
| Title | S9912 Combination Chemo in Stage III Ovarian Cancer, |
| Official title | Phase II Evaluation of Intravenous Paclitaxel, Intraperitoneal Cisplatin, Intravenous Liposomal Doxorubicin and Intraperitoneal Paclitaxel in Women With Optimally-Debulked Stage III Epithelial Ovarian Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | cisplatin, liposomal doxorubicin, paclitaxel |
| Enrollment | 68 |
| Start date | Sep 1, 1999 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 4, 2013 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: